Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247279 | 1.00 | PDK2 (0.34) | PDK2HTR2CCYP11B1HPGDSDHODH | |
| SCHEMBL12247278 | 0.92 | PDK2 (0.35) | PDK2HTR2CHPGDS | |
| SCHEMBL12247268 | 0.92 | PDK2 (0.35) | PDK2HTR2CHPGDS | |
| SCHEMBL12247026 | 0.92 | PDK2 (0.33) | PDK2CYP11B1HPGDSDHODH | |
| SCHEMBL12247298 | 0.92 | PDK2 (0.39) | PDK2HTR2CHPGDS | |
| SCHEMBL12247266 | 0.91 | HTR2C (0.39) | PDK2HTR2CCYP11B1HPGDSDHODH | |
| SCHEMBL13459686 | 0.91 | HTR2C (0.39) | PDK2HTR2CCYP11B1HPGDSDHODH | |
| SCHEMBL12247282 | 0.90 | PDK2 (0.40) | PDK2HTR2CHPGDS | |
| SCHEMBL12247260 | 0.90 | PDK2 (0.40) | PDK2HTR2CHPGDS | |
| SCHEMBL12247263 | 0.89 | KDM4E (0.36) | PDK2HTR2CCYP11B1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8525158-B2 | Anthracene derivative and organic electroluminescence element using the same | DOOSAN CORPORATION (KR) | 2013-09-03 | — | — | US | disclosed |
| US-8525158-B2 | Anthracene derivative and organic electroluminescence element using the same | DOOSAN CORPORATION (KR) | 2013-09-03 | — | — | US | disclosed |
| US-20110210320-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | DOOSAN CORPORATION (KR) | 2011-09-01 | — | — | US | disclosed |
| US-20110210320-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | DOOSAN CORPORATION (KR) | 2011-09-01 | — | — | US | disclosed |
| WO-2010027181-A2 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | 주식회사 두산 (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110210320-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | KCNJ2, KCNJ1, BRD4 | PDK2 646/4885HTR2C 3096/4885CYP11B1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.